Vojtech Melenovsky1, Seok-Jae Hwang2, Grace Lin2, Margaret M Redfield2, Barry A Borlaug2. 1. Division of Cardiovascular Diseases, Department of Medicine, Mayo Clinic, Rochester, MN, USA Department of Cardiology, Institute of Clinical and Experimental Medicine - IKEM, Videnska 1958/9, Prague 4 140 28, Czech Republic vojtech.melenovsky@ikem.cz. 2. Division of Cardiovascular Diseases, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
Abstract
AIM: Right heart function is not well characterized in patients with heart failure and preserved ejection fraction (HFpEF). The goal of this study was to examine the haemodynamic, clinical, and prognostic correlates of right ventricular dysfunction (RVD) in HFpEF. METHODS AND RESULTS: Heart failure and preserved ejection fraction patients (n = 96) and controls (n = 46) underwent right heart catheterization, echocardiographic assessment, and follow-up. Right and left heart filling pressures, pulmonary artery (PA) pressures, and right-sided chamber dimensions were higher in HFpEF compared with controls, while left ventricular size and EF were similar. Right ventricular dysfunction (defined by RV fractional area change, FAC <35%) was present in 33% of HFpEF patients and was associated with more severe symptoms and greater comorbidity burden. Right ventricular function was impaired in HFpEF compared with controls using both load-dependent (FAC: 40 ± 10 vs. 53 ± 7%, P < 0.0001) and load-independent indices (FAC adjusted to PA pressure, P = 0.003), with enhanced afterload-sensitivity compared with controls (steeper FAC vs. PA pressure relationship). In addition to haemodynamic load, RVD in HFpEF was associated with male sex, atrial fibrillation, coronary disease, and greater ventricular interdependence. Over a median follow-up of 529 days (IQR: 143-1066), 31% of HFpEF patients died. In Cox analysis, RVD was the strongest predictor of death (HR: 2.4, 95% CI: 1.6-2.6; P < 0.0001). CONCLUSION: Right heart dysfunction is common in HFpEF and is caused by both RV contractile impairment and afterload mismatch from pulmonary hypertension. Right ventricular dysfunction in HFpEF develops with increasing PA pressures, atrial fibrillation, male sex, and left ventricular dysfunction, and may represent a novel therapeutic target. Published on behalf of the European Society of Cardiology. All rights reserved.
AIM: Right heart function is not well characterized in patients with heart failure and preserved ejection fraction (HFpEF). The goal of this study was to examine the haemodynamic, clinical, and prognostic correlates of right ventricular dysfunction (RVD) in HFpEF. METHODS AND RESULTS:Heart failure and preserved ejection fraction patients (n = 96) and controls (n = 46) underwent right heart catheterization, echocardiographic assessment, and follow-up. Right and left heart filling pressures, pulmonary artery (PA) pressures, and right-sided chamber dimensions were higher in HFpEF compared with controls, while left ventricular size and EF were similar. Right ventricular dysfunction (defined by RV fractional area change, FAC <35%) was present in 33% of HFpEF patients and was associated with more severe symptoms and greater comorbidity burden. Right ventricular function was impaired in HFpEF compared with controls using both load-dependent (FAC: 40 ± 10 vs. 53 ± 7%, P < 0.0001) and load-independent indices (FAC adjusted to PA pressure, P = 0.003), with enhanced afterload-sensitivity compared with controls (steeper FAC vs. PA pressure relationship). In addition to haemodynamic load, RVD in HFpEF was associated with male sex, atrial fibrillation, coronary disease, and greater ventricular interdependence. Over a median follow-up of 529 days (IQR: 143-1066), 31% of HFpEF patients died. In Cox analysis, RVD was the strongest predictor of death (HR: 2.4, 95% CI: 1.6-2.6; P < 0.0001). CONCLUSION: Right heart dysfunction is common in HFpEF and is caused by both RV contractile impairment and afterload mismatch from pulmonary hypertension. Right ventricular dysfunction in HFpEF develops with increasing PA pressures, atrial fibrillation, male sex, and left ventricular dysfunction, and may represent a novel therapeutic target. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Jaroslav Meluzin; Lenka Spinarová; Petr Hude; Jan Krejcí; Vladimír Kincl; Roman Panovský; Ladislav Dusek Journal: J Am Soc Echocardiogr Date: 2005-05 Impact factor: 5.251
Authors: M A Quinones; A D Waggoner; L A Reduto; J G Nelson; J B Young; W L Winters; L G Ribeiro; R R Miller Journal: Circulation Date: 1981-10 Impact factor: 29.690
Authors: Mariëlle C van de Veerdonk; Taco Kind; J Tim Marcus; Gert-Jan Mauritz; Martijn W Heymans; Harm-Jan Bogaard; Anco Boonstra; Koen M J Marques; Nico Westerhof; Anton Vonk-Noordegraaf Journal: J Am Coll Cardiol Date: 2011-12-06 Impact factor: 24.094
Authors: Carolyn S P Lam; Peter E Carson; Inder S Anand; Thomas S Rector; Michael Kuskowski; Michel Komajda; Robert S McKelvie; John J McMurray; Michael R Zile; Barry M Massie; Dalane W Kitzman Journal: Circ Heart Fail Date: 2012-08-10 Impact factor: 8.790
Authors: Anna R Hemnes; Karen B Maynard; Hunter C Champion; Linda Gleaves; Niki Penner; James West; John H Newman Journal: Pulm Circ Date: 2012-07 Impact factor: 3.017
Authors: Sanjiv J Shah; Dalane W Kitzman; Barry A Borlaug; Loek van Heerebeek; Michael R Zile; David A Kass; Walter J Paulus Journal: Circulation Date: 2016-07-05 Impact factor: 29.690
Authors: Yogesh N V Reddy; Rickey E Carter; Masaru Obokata; Margaret M Redfield; Barry A Borlaug Journal: Circulation Date: 2018-08-28 Impact factor: 29.690
Authors: Maximilian von Roeder; Johannes Tammo Kowallick; Karl-Philipp Rommel; Stephan Blazek; Christian Besler; Karl Fengler; Joachim Lotz; Gerd Hasenfuß; Christian Lücke; Matthias Gutberlet; Holger Thiele; Andreas Schuster; Philipp Lurz Journal: Clin Res Cardiol Date: 2019-05-03 Impact factor: 5.460
Authors: Kotaro Nochioka; Gabriela Querejeta Roca; Brian Claggett; Tor Biering-Sørensen; Kunihiro Matsushita; Chung-Lieh Hung; Scott D Solomon; Dalane Kitzman; Amil M Shah Journal: JAMA Cardiol Date: 2018-10-01 Impact factor: 14.676